Observational Study
Copyright ©The Author(s) 2022.
World J Hepatol. Jul 27, 2022; 14(7): 1495-1503
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1495
Table 1 Patient characteristics at the start of treatment
Characteristic
n = 40
Gender [male; n (%)]31 (77.5)
Age [yr; median (range)]46.5 (24-63)
Severity of opioid use disorder
Abstinent, n (%)16 (40.0)
User, n (%)21 (52.5)
Abuser, n (%)3 (7.5)
Concomitant opioid agonist maintenance therapy
Metadone, n (%)35 (87.5)
Buprenorfine, n (%)1 (2.5)
None (previous history), n (%)4 (10.0)
History of alcohol abuse, n (%)14 (35.0)
Concomitant psychoactive drugs, n (%)17 (42.5)
HCV genotype
1a, n (%)21 (52.5)
3, n (%)18 (45.0)
4, n (%)1 (2.5)
Liver disease staging1
F0, n (%)8 (22.9)
F1, n (%)12 (34.3)
F2, n (%)6 (17.1)
F3, n (%)5 (14.3)
F4, n (%)4 (11.4)